MedTrace Logo

Hypotension After Anesthetic Induction with Remimazolam in Elderly

NCT05538741 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-09-19

No results posted yet for this study

Summary

Even though remimazolam is known to be safely administered without hemodynamic instability, hypotension is the one of the common side effects of remimazolam. Because elderly patients are susceptible to hypotension due to old age, multimodality, and multiple medications, hypotension can be harmful in elderly patients. Remimazolam can be administered either bolus or continuous for anesthetic induction. In our study the investigators aimed to compare the incidence of hypotension after anesthetic induction using remimazolam by bolus injection and continuous infusion in elderly patients.

Conditions

Interventions

DRUG

Bolus of remimazolam

0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for \>80 years old

DRUG

Continuous infusion of remimazolam

12 mg/kg/hr until loss of consciousness

Sponsors & Collaborators

  • Kangbuk Samsung Hospital

    lead OTHER

Principal Investigators

  • Eunah Cho, PhD · Assistant Professor

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-14
Primary Completion
2024-06-14
Completion
2024-06-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05538741 on ClinicalTrials.gov